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We identified 86 patients that met our inclusion criteria. Median follow-up in alive 
patients was 44 months. Eighty-five percent of patients had stage III disease, and 94% 
received sequential or concurrent chemotherapy. The median RT dose was 6400cGy in 32 
fractions (range 4600cGy to 8400cGy). The median time from the end of RT to PET scan 
was 3.4 months. The residual median SUVmax, SUV average, MTV and TLG were 4.7, 
2.7, 19.3 and 58822, respectively. Local failure-free survival (LFFS) and overall survival 
(OS) at 3 years were 39% and 37%, respectively. Using the median values as a cut-off, 
lower SUVmax (p=0.003), SUVaverage (p=0.002) and TLG (p=0.02) were significantly 
correlated with better LFFS, but MTV was not. Lower SUV max was associated with 
improved OS (p=0.03), with a trend of SUV average and TLG towards improved OS. 
MTV was not predictive of OS. The only dosimetric factor associated with improved 
LFFS and OS was RT dose ≥6000cGy. Tumor size, stage, histology, KPS or concurrent vs 
sequential chemotherapy were not significantly associated with LFFS or OS. Conclusion: 
Residual SUVmax, SUV average, and TLG of the primary tumor within 6 months after 
definitive RT appear to be associated with residual disease and high local failure rates, 
while MTV is not a good surrogate for LFFS and OS.
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O-018: A MOLECULAR EPIDEMIOLOGY STUDY IN ASIAN  
PATIENTS WITH ADVANCED NSCLC OF ADENOCARCINOMA 
HISTOLOGY TO ASSESS EGFR MUTATION STATUS: PIONEER 
STUDY (THAILAND DATA)
Sumitra Thongprasert1, Sarayut L. Geater2, Vichien Srimuninnimit3, Virote Sriuranpong4  
1Chiang Mai University, Chiang Mai/THAILAND, 2Prince Of Songkla, Hat Yai/
THAILAND, 3Siriraj Hospital, Bangkok/THAILAND, 4, Chulalongkorn University, 
Bangkok/THAILAND
Background: Lung cancer is the leading cause of death in Thai population and its 
incidence is increasing every year. EGFR mutation is an important biomarker to predict 
effectiveness of EGFR-TKI drug as patients with mutation positive have better response 
than ones without. Previously published data revealed that EGFR mutations were 
frequently found in Asian female NSCLC patients with adenocarcinoma histology or never 
smokers. Thus, this study aims to examine the mutation status and its correlation with 
demographic data and smoking history in Thai population to provide useful information 
to clinicians for making treatment decision. Methods: Thai NSCLC patients who have 
histologically or cytologically confirmed advanced (stage IIIb/IV) of adenocarcinoma 
histology and able to provide cancer tissue or cytology sample and treatment naïve were 
screened. Informed consent was obtained from each patient before any study procedures 
were performed. Demographic data, smoking history and disease stage were collected. All 
available tissue or cytology samples were tested by SCORPION ARMS method. Results: 
119 Thai ethnic patients from 4 participating sites were enrolled to the study. 67 (56.3%) 
were males and 52 (43.7%) were females. The mean (SD) age of the patients was 60.3 yrs 
(12.3) with a minimum of 19 yrs and maximum of 85 yrs. The total number of patients 
who never smoked was 43 (36.1%), ex-smokers was 52 (43.7%), occasional smokers was 6 
(5%) and regular smokers was 18 (15.1%). Among patients with smoking history (76), mean 
(SD) pack-years was 27.7 (38.7). 97 out of 119 (81.5%) patients had a metastatic disease at 
original diagnosis. Out of 117 patients with successful EGFR mutation test, EGFR mutation 
status was found to be positive in 63 (53.8%) and negative in 54 (46.2%). Out of 63 patients 
with positive status, 33 patients (63.5%) were female. Among all clinical factors only 
smoking history was significantly correlated with EGFR mutation status. Never-smokers 
significantly correlated with positive EGFR test (p=0.03). Conclusion: Prevalence of 
EGFR mutation in Thai NSCLC patients was 53.8%. Smoking history was reported as an 
only correlated factor of positive EGFR mutation test in this study. Other clinical factors 
(e.g. gender) reported in previous studies to have strong correlation with EGFR mutation 
status could not be demonstrated here. The discrepancy might be due to limited number of 
subjects. A larger sample size is warranted for result confirmation.
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O-019: NOVEL MOLECULAR PROPERTIES IN ACQUIRING RESIS-
TANCE TO EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS
Kazuhiko Shien1, Shinichi Toyooka1, Junichi Soh1, Hiromasa Yamamoto1, Masashi 
Furukawa1, Eiki Ichihara2, Masaomi Yamane1, Takahiro Oto1, Katsuyuki Kiura2, 
Shinichiro Miyoshi1  
1Department Of Thoracic Surgery, Okayama University Graduate School Of Medicine, 
Dentistry And Pharmaceutical Sciences, Okayama/JAPAN, 2Department Of Hematology, 
Oncology And Respiratory Medicine, Okayama University Graduate School Of Medicine, 
Dentistry And Pharmaceutical Sciences, Okayama/JAPAN
Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) 
show remarkable response to drug sensitive EGFR-mutant lung cancer. However, acquired 
resistance to EGFR-TKIs is a critical problem in the treatment of lung cancer. While 
several mechanisms have been demonstrated to be responsible for acquired resistance, all 
mechanisms have not been uncovered. The purpose of this study was to indentify novel 
property of the acquired resistance and to explore the possibility of therapeutic strategy 
for acquired EGFR-TKI resistant lung cancer. Methods: EGFR mutant cell lines, HCC827 
(exon 19 deletion), PC-9 (exon 19 deletion), HCC4006 (exon 19 deletion), and HCC4011 
(L858R point mutation), were exposed to gefitinib with two different manners, stepwise 
escalation and high concentration exposure methods, and resistant cells to gefitinib were 
established. The molecular profiles, cellular phenotypes, and sensitivity to various drugs 
of established resistant cells were characterized. Results: With the stepwise escalation 
method, MET amplification was found in HCC827 and HCC4011 derived resistant 
sublines (HCC827-GRS and HCC4011-GRS) and T790M mutation was found in the PC-9 
derived subline (PC-9-GRS). Epithelial-to-mesenchymal transition (EMT) was observed 
in HCC4006 derived subline (HCC4006-GRS). With high concentration method, EMT 
was observed in HCC827 and HCC4006 derived sublines (HCC827-GRH and HCC4006-
GRH). MET amplification was found in HCC4011 derived subline (HCC4011-GRH). 
No specific molecular alteration was indentified in PC-9 derived subline (PC-9-GRH). 
Establishment of resistant cells with two different methods was performed twice or 
more to confirm reproducibility. Next, we investigated the detail of cellular properties of 
resistant sublines using mainly HCC827 and PC-9 derived cells. Of particular interest, 
we found stem-cell like properties including up-regulation of aldehyde dehydrogenase 
isoform 1 expression, sphere formation capability, and increased rate of side population 
using Hoechst 33342 staining only in HCC827-GRH not in other resistant sublines 
such as HCC827-GRS and PC-9 derivatives. In addition, multidrug resistance protein 1 
protein was also up-regulated in HCC827-GRH and acquired high degree of resistance to 
taxanes compared to their parental cells. On the other hand, the cyclopamine which was 
an antagonist of Smoothened protein, an important component of Hedgehog pathway, 
showed inhibition of cell viability in HCC827-GRH compared with in parental HCC827. 
Conclusion: Our study indicates that cellular environment in acquiring resistance to 
EGFR-TKI influences molecular and cellular features of resistant cells. As a novel feature 
of acquired resistant cells, we identify the stem-cell like property which can be is a 
therapeutic target of overcoming resistance.
Keywords: EGFR mutation, Tyrosine kinase inhibitor, acquired resistance, non-small cell 
lung cancer
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O-020: SYNERGISTIC INTERACTIONS OF GEFITINIB, AFATINIB, 
CETUXIMAB AND DASATINIB AGAINST GEFITINIB RESISTANT 
NON-SMALL CELL LUNG CANCER (NSCLC)
Alex Y. Chang1, Miao Wang2  
1Medical Oncology, Johns Hopkins University, Baltimore/MD/UNITED STATES OF 
AMERICA, 2Medical Oncology, Johns Hopkins Singapore/SINGAPORE
Background: NSCLC eventually developed resistance to chemotherapy and targeted 
agents, even to EGFR TKI (such as gefitinib or erlotinib) by EGFR activating mutation 
positive cells. Thus, there are limits in the efficacy of these agents. Various mechanisms of 
resistance, such as secondary mutation (e.g. T790M), C-MET amplification or alternative 
pathways have been reported. It is imperative to elucidate mechanism of resistance in 
order to overcome. Preclinical and clinical studies reported that combining cetuximab and 
afatinib could overcome resistance in NSCLC with sensitive EGFR mutation or responding 
to EGFR TKI and relapsed. The molecular mechanism is not very clear.  Methods: The 8 
cell lines with the following molecular characteristics were used in MTT assay for anti-
proliferative activity: A549: EGFR WT, HER-2 WT, K-ras mutant 
H1975: EGFR L858R + T790M 
H1650: EGFR exon 19 del (del E746-A750) + deletion of Exon 9 in PTEN 
HCC827: EGFR exon 19 del 
H820: EGFR exon 19 del, +T790M + C-MET amplification 
AS13: EGFR L858R+ exon 20 (R776C) missense mutation, K-ras WT 
AS87: EGFR WT, K-ras-WT 
AS125: EGFR WT, K-ras WT We evaluated 8 NSCLC cell lines to determine the sensitivity 
and resistance mechanisms to different targeted agents. We report here the results of 
gefitinib, afatinib, cetuximab and dasatinib. IC50 of each cell line treated with each drug 
was determined either alone or in combination. We also evaluated the protein expression 
in the signal pathways, mutation analysis, apoptosis, cell functions of adhesion, migration 
and invasion. Results: Dasatinib and Afatinib have stronger anti-proliferative activity 
against A549, H1975 (EGFR L858R + T790M), H820, AS87 and AS125 than cetuximab or 
gefitinib. HCC827 was sensitive to all 4 drugs. AS13 was only sensitive to dasatinib and 
resistant to 3 EGFR inhibitors. Combination of dasatinib and afatinib was synergistic 
against both H1975 and H1650. However, cetuximab and afatinib combination was 
synergistic against H1975 but not H1650, while H1650 was resistant to all 4 agents when 
used alone. Conclusion: Our preliminary results suggested a combination of Cetuximab 
and afatinib is synergistic to very specific NSCLC cells while dasatinib and afatinib may 
have broader activity. Other data are forthcoming.
Keywords: synergistic interaction of targeted agents, NSCLC, Overcome resistance
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O-021: COMBINED THERAPY WITH NEXT GENERATION EGFR 
INHIBITOR AND MET KINASE INHIBITOR FOR OVERCOMING 
THE RESISTANCE IN EGFR MUTANT LUNG CANCER
Shigeki Nanjo, Tadaaki Yamada, Takayuki Nakagawa, Shinji Takeuchi, Tetsuya 
Mitsudomi, Seiji Yano  
Division Of Medical Oncology, Cancer Research Institute, Kanazawa University, 
Kanazawa/JAPAN
Background: Although the epidermal growth factor receptor tyrosine kinase inhibitors 
(EGFR-TKIs) erlotinib and gefitinib have shown dramatic effects against EGFR mutant 
lung cancer, acquired resistance to EGFR-TKIs is a serious problem in the management 
of EGFR mutant lung cancer. Of them, half of patients were induced the resistance by 
gatekeeper EGFR-T790M mutation. In addition, next generation inhibitors, irreversible and 
mutant-selective EGFR-TKIs are expected to overcome the reversible EGFR-TKI resistance. 
Previous reports demonstrated that EGFR-T790M mutation can coexist other resistance 
mechanisms, Met amplification and HGF overexpression. Therefore, the bypass signaling 
via HGF/Met might diminish the efficacy of next generation EGFR-TKIs in previous 
clinical trials. ALK and Met inhibitor crizotinib has become a standard therapy for lung 
cancer patients with EML4-ALK rearrangement. In this study, we investigate whether dual 
inhibition of Met and EGFR could overcome the EGFR-TKI resistance in EGFR mutant 
lung cancer cells. Methods: We examined the efficacy of combined therapy with the next 
generation EGFR-TKIs (afatinib or WZ4002), and crizotinib in the EGFR-TKI resistance 
cells harboring with EGFR mutation, H1975/HGF (HGF gene transfection and both L858R 
activating mutation and T790M secondary mutation in EGFR) and HCC827ER (Exon 
19 deletion in EGFR and Met amplification). Results: The next generation EGFR-TKI 
(afatinib or WZ4002) inhibited the growth of H1975 and HCC827, but not H1975/HGF 
and HCC827ER resistance cells. HGF overexpression and Met amplification triggered 
the resistance of H1975 and HCC827 cells to afatinib or WZ4002, whereas crizotinib 
sensitized H1975/HGF, HCC827ER, and HGF-treated H1975 and HCC827 cells to afatinib, 
inhibiting EGFR and Met phosphorylation and their downstream molecules. Combined 
treatment potently inhibited the growth of tumors induced in SCID mice by H1975 and 
H1975/HGF cells. These therapeutic effects were associated with the inhibition of EGFR 
and Met phosphorylation in vivo. Conclusion: The combination of next generation EGFR-
TKI and crizotinib may overcome HGF/Met and/or EGFR-T790M triggered resistance to 
EGFR-TKIs and may result in more successful treatment of patients with EGFR-mutant 
lung cancers. Further evaluations in clinical trials are warranted. 
Keywords: next generation EGFR-TKI resistance, crizotinib, HGF, Met amplification
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O-022: NCIC CTG IND.196: PHASE I STUDY OF FORETINIB 
(GSK1363089) AND ERLOTINIB IN PATIENTS WITH ADVANCED 
PRETREATED NSCLC
Natasha Leighl, Ming Tsao, Cheryl Ho, Frances Shepherd, Nevin Murray, John Goffin, 
Garth Nicholas, Lesley Seymour, Glenwood Goss, Penelope Bradbury  
NCIC Clinical Trials Group, Toronto/ON/CANADA
Background: MET is a potential mediator of resistance to epidermal growth factor receptor 
tyrosine kinase inhibitors (EGFR TKIs) in non-small cell lung cancer (NSCLC). Foretinib 
is an oral multikinase-inhibitor of MET, RON, AXL, TIE-2 and VEGFR. Methods: IND196 
evaluated the RP2D of foretinib plus erlotinib as continuous oral daily dosing in previously 
treated advanced NSCLC patients. Secondary objectives included safety, tolerability (NCI 
CTCAE V4), pharmacokinetics (PK), response (RECIST 1.1) and potential predictive 
biomarkers of response including EGFR and KRAS mutation, MET and circulating HGF. 
For PK evaluation, erlotinib was started on day 1 cycle 1 and foretinib on day 14 cycle 
1. Dose limiting toxicity (DLT) was defined as drug-related grade>=3 non-hematologic 
toxicity (excluding alopecia, inadequately controlled diarrhea, nausea/vomiting, rash 
and hypertension) in cycle 1, or cycle 2 treatment delay >= 2 weeks). Results: 31 subjects 
(median age 63; ECOG PS 0:1:2=7:23:1) were enrolled on 3 dose levels (DL) of daily 
foretinib/erlotinib, DL1: 30 mg/100 mg (n=9); DL2: 30mg/50mg (n=15); DL3: 45 mg/150 mg 
(n=7). Five patients were inevaluable for DLT and were replaced. No dose limiting toxicities 
(DLT) were seen in 3 evaluable patients treated in DL1. In DL2, 2 additional patients had 
DLT (grade 3 pain/mucositis; fatigue/cycle 2 delay), but dose reductions/holds were reduced 
compared with DL3 (27%). Erlotinib and foretinib-related adverse events occurring in 
>20% included diarrhea, fatigue, anorexia, dry skin, rash, and hypertension. Final PK 
indicated no significant interaction with the combination (foretinib C max [ng/mL] Day 14/ 
Day 28- DL1 1718.8/2387.2; DL2 2335.3/2645.4; DL3 2236.8/2472.1). On review of adverse 
events, PK and dose intensity, DL2 was considered the RP2D of the combination following 
14 days of single agent erlotinib. Among 27 response eligible patients, 3 partial responses 
were seen (11%). Evaluation of EGFR, KRAS mutations, MET and circulating HGF is 
underway. Conclusion: The RP2D of continuous daily erlotinib plus foretinib in pretreated 
advanced NSCLC patients is erlotinib 150 mg daily plus foretinib 30 mg daily in patients 
who tolerated 14 days of single agent erlotinib. Treatment related AEs requiring dose 
holds/reductions were common with the combination. Additional biomarkers of benefit of 
foretinib plus erlotinib are under exploration.
Keywords: NSCLC, phase I, Erlotinib, MET inhibitor
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O-023: EFFICACY, SAFETY, AND PATIENT-REPORTED OUT-
COMES OF FIRST-LINE DACOMITINIB (PF-00299804), AN 
IRREVERSIBLE PAN-HER TYROSINE KINASE INHIBITOR, IN 
PATIENTS WITH LUNG CANCERS HARBORING EGFR EXON 21 
MUTATION OR EGFR EXON 19 DELETION 
Tony Mok1, Mark G. Kris2, Sai-hong I. Ou3, Renato G. Martins4, Dong-wan Kim5, Zelanna 
Goldberg6, Hui Zhang7, Ian Taylor8, Joseph O’Connell9, Jim Doherty9, Pasi A. Janne10  
1Department Of Clinical Oncology, The Chinese University Of Hong Kong, Shatin/HONG 
KONG, 2Memorial Sloan-Kettering Cancer Center, New York/NY/UNITED STATES 
OF AMERICA, 3Medicine-Hematology/Oncology, Chao Family Comprehensive Cancer 
Center/University Of California Irvine, Orange/CA/UNITED STATES OF AMERICA, 
4University Of Washington, Seattle/WA/UNITED STATES OF AMERICA, 5Department 
Of Internal Medicine, Seoul National University Hospital, Seoul/KOREA, 6Pfizer 
Oncology, La Jolla/CA/UNITED STATES OF AMERICA, 7Pfizer (China) Research & 
Development Co Ltd, Shangahi/CHINA, 8Pfizer Oncology, Groton/UNITED STATES OF 
AMERICA, 9Pfizer Oncology, New York/NY/UNITED STATES OF AMERICA, 10Dana-
Farber Cancer Institute, Boston/MA/UNITED STATES OF AMERICA
Background: Dacomitinib irreversibly inhibits EGFR/HER1, HER2 and HER4, and 
showed superior activity versus reversible EGFR tyrosine kinase inhibitors in EGFR-
mutant lung cancer models, including resistant forms. This open-label Phase II study 
evaluates dacomitinib as first-line treatment for patients with lung cancers. Patients with 
sensitizing EGFR deletions/mutations in exons 19 or 21 are reported here, as is the first 
presentation of patient-reported outcome (PRO) data. Methods: Patients had stage IIIB/
IV adenocarcinoma, no prior systemic treatment, had smoked <10 pack years (none within 
15 years of enrollment) or had known EGFR mutation. Patients received dacomitinib 
orally once daily continuously at 45 mg, or 30 mg with the option to escalate to 45 mg; 
evaluation was every 28 days. Endpoints included progression-free survival rate at 4 
months (PFS@4M, primary); PFS, objective response rate (ORR), overall survival and 
PROs. PROs were assessed using the European Organisation for Research and Treatment 
of Cancer (EORTC) questionnaire (QLQ-C30, core module) and lung cancer module 
(QLQ-LC13) at baseline, day 1 of each cycle, and at the end of treatment. Results: 89 
patients have been enrolled and treated; 46 had EGFR mutation in exons 19 (n=25) or 21 
(n=21), 32 were female and 26 Asian. 34/46 evaluable patients with EGFR exon 19 deletion 
or 21 mutation had a PR (ORR = 74%; 95% CI: 59–86; exon 19 = 72%; exon 21 = 76%). ORR 
and preliminary PFS were not significantly different for exons 19 and 21. Preliminary 
PFS@4M was 96% (95% CI: 84–99), preliminary PFS rate at 12 months was 75% (95% CI: 
59–85) and preliminary median PFS was 17 months (95% CI: 13–22). Median duration of 
treatment was 14.7 months. Preliminary overall survival data will be presented as available. 
For patients with EGFR wild-type lung cancers, ORR and PFS@4M rates were 7% (n=14; 
95% CI: 0–34) and 33% (n=14; 95% CI: 11–58), respectively, and for patients with EGFR 
unknown lung cancers, 46% (n=22; 95% CI: 24–68) and 68% (n=22; 95% CI: 45– 83), 
respectively. Of 7 patients with non-sensitizing EGFR mutations; 2 had a PR and 3 SD. For 
all 89 patients, common side effects included dermatitis acneiform (grade 3/4 = 19.1%/0) 
and diarrhea (14.6%/0). 3/46 patients with EGFR exon 19 or 21 mutations discontinued 
treatment due to drug-related toxicity. By patient report, dacomitinib treatment was 
associated with early and durable improvement in cough, dyspnea, fatigue, and pain in 
chest versus baseline at specific assessment timepoints; diarrhea, alopecia and mucositis/
stomatitis (QLQ-C30/LC13) were tolerable and improved over time. Conclusion: 74% 
of patients in this cohort with EGFR exon 19 or 21 mutant lung cancers experienced PRs 
with first-line dacomitinib; preliminary PFS rate was 75% at 1 year; preliminary median 
PFS was 17 months; and dacomitinib was associated with NSCLC symptom relief. Further 
research is planned in this patient population.
Keywords: first-line therapy, dacomitinib, Patient-reported outcomes, EGFR-mutant 
NSCLC
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O-024: COMPARISON OF IMMUNOHISTOCHEMISTRY, FISH, RT-
PCR METHODOLOGIES FOR DETECTION OF EML4-ALK FUSION 
GENE IN ADVANCED NON-SMALL CELL LUNG CARCINOMA
Xiao-hong Han1, Li Ma2, Yutao Liu2, Ningning Zhang2, Dan Li2, Yuankai Shi2  
1Medical Of Oncology, Cancer Hospital/Institute, Chinese Academy Of Medical Sciences 
& Peking Union Medical College, Beijing/CHINA, 2Medical Oncology, Cancer Institution, 
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Background: Echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma 
kinase (EML4-ALK) gene rearrangements are detected in 3% to 13% of non-small cell 
lung carcinomas. Accurate testing for detection of EML4-ALK fusions is essential for 
ALK inhibitors therapy selection in advanced non-small cell lung carcinoma patients. We 
investigated ALK rearrangement using Immunohistochemistry assay (IHC), transcription-
polymerase chain reaction (RT-PCR), and Fluorescent in situ hybridization (FISH) in order 
to compare immunohistochemistry, FISH, RT-PCR methodologies for detection of ALK 
rearrangement. Methods: One hundred twenty seven paired tumor samples with advanced 
NSCLC were collected from Cancer Institute/Hospital of Chinese Academy of Medical 
Sciences. All of these patients who previously received cell cytotoxic regimens therapy had 
progressive disease. ALK protein was detected by IHC using new clone antibody (D5F3, 
Cell Signal Techonology, USA). ALK gene rearrangement was evaluated by FISH using 
Vysis ALK Break Apart FISH Probe kit (Abbott, USA) and RT-PCR using AmoyDx ALK 
gene rearrangement kit (AmoyDx, China). Results: 119 samples can be evaluated by IHC 
and FISH in 127 cases (93.7%). ALK positive samples were 39.5% (47/119) by IHC, and ALK 
rearrangement samples were 37.8% (45/119) by FISH. The concordance rate is 95% (kappa 
= 0.894, p < 0.001). All 66 IHC 0 samples were FISH-, 37 of 39 (94.9%) IHC 3+ samples were 
FISH +, 7 of 8 (87.5%) IHC 2+ samples were FISH +, whereas 1 of 6 (16.7%) IHC 1+ samples 
were FISH +. Considering FISH as a standard testing, sensitivity and specificity of IHC 
were 95.6% and 94.6%, respectively, when 2+ and 3+ were regarded as IHC positive and 
0 and 1+ as IHC negative. 105 samples can be evaluated by RT-PCR in 119 cases (88.2%). 
EML4-ALK variant were detectable by RT-PCR in 32.4% (34 / 105) which were completely 
agreement with FISH and IHC. There are 6 negative cases by RT-PCR with ALK positive 
by IHC and FISH, and 1 positive case by RT-PCR and IHC but negative by FISH. The 
sensitivity and specificity of RT-PCR were 84.6% and 98.5%, respectively. The concordance 
rate is 93.3% (kappa = 0.853, p < 0.001). ALK-positive patients were significantly associated 
with female (p = 0.033), young (p = 0.015) and higher histological grade (p = 0.012) patients. 
Conclusion: IHC can be a useful screening algorithm to evaluate ALK rearrangement 
in NSCLC screening for ALK targeted therapy. RT-PCR showed relatively higher false 
negative rate for ALK rearrangement. FISH was the most sensitive method for different 
ALK rearrangement.
Keyword: NSCLC, Immunohistochemistry, Fluorescent in situ hybridization,RT-
PCR,ALK
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O-025: A RETROSPECTIVE STUDY OF CLINICOPATHOLOGIC 
FACTORS ASSOCIATED WITH ALK REARRANGEMENT AND SUR-
VIVAL OUTCOME IN CHINESE PATIENTS WITH NSCLC
Xu-chao Zhang1, Carolyn Blanckmeister2, Ying Cheng3, Di Wu3, Jin-ji Yang4, Hong-xia 
Tian4, Jie Chen5, Zhi Xie4, Hong-hong Yan4, Yi-long Wu4  
1Rm 1016, Imaging Bldg, Guangdong General Hospital, Guangdong Lung Cancer Insitute, 
Guanggong General Hospital And Guangdong Academy Of Medical Sciences, Guangzhou/
CHINA, 2Pfizer Oncology, New York/NY/UNITED STATES OF AMERICA, 3Jilin 
Provincial Cancer Hospital, Jilin/CHINA, 4Guangdong General Hospital, Guangdong 
Academy Of Medical Sciences, Guangzhou/CHINA, 5Pfizer Oncology, Groton/UNITED 
STATES OF AMERICA
Background: We tested 400 NSCLC pts for ALK, EGFR and KRAS status and correlated 
clinical factors with ALK status and overall survival (OS). Methods: ALK was assessed 
using RACE-PCR, IHC and FISH; EGFR and KRAS status were assessed by direct DNA 
sequencing. OS was estimated by the Kaplan-Meier method. Results: Consecutive and 
unselected cases from south (n=294) and north (n=106) China were tested; 31 (7.7%), 
105 (26.2%) and 33 (8.2%) pts were ALK+, EGFR+ and KRAS+, respectively. ALK and 
EGFR aberrations were largely exclusive (P=0.009); 2 cases were ALK+/EGFR+. ALK+ was 
associated with female sex (P=0.023), non/light-smoking (P=0.001) and adenocarcinoma 
(P=0.017), and was more prevalent in southern (9.2%; 27/294) than northern (3.8%; 
4/106) pts. The ALK fusion partner was EML4 in all 31 cases; predominantly variants 
V1–3 (90.3%, 28/31). In 326 modeled pts, female sex (HR=2.84; P=0.022), wild type EGFR 
(HR=15.87; P=0.001), non/light-smoking (HR=3.95; P=0.021) and adenocarcinoma 
(HR=4.12; P=0.031) were associated with ALK+. Of 225 cases evaluated by IHC and RACE-
PCR, IHC sensitivity was 100% (19/19; [5 IHC+; 10 IHC++; 4 IHC+++]) and specificity was 
80.8% (160/198). All 19 ALK+ cases by RACE-PCR were also ALK+ by FISH. In the first 303 
pts, there were no significant OS differences between ALK+, EGFR+, KRAS+ and triple-
negative pts, between ALK+ and -negative pts, or between ALK+ cases matched with non-
TKI-treated controls balanced for disease stage, sex, histology and EGFR/KRAS status. In 
ALK+ pts, non/light-smoking status (P=0.016) and prior surgery (P=0.024) were associated 
with increased OS by log rank test. In a Cox model, disease stage (P≤0.001 for both stage I 
and II), and surgical treatment (P=0.001) were prognostic for OS. Conclusion: ALK fusion 
prevalence was 7.7% overall, and was higher in southern pts. ALK+ was associated with 
non/light-smoking, adenocarcinoma and female sex. ALK fusion variants were mostly 
V1–3, which may inform RT-PCR screening. IHC for ALK protein and FISH for ALK 
rearrangement may be useful for patient selection. ALK+ was not a favorable prognostic 
factor, although disease stage and smoking history may influence OS in ALK+ NSCLC.
Keywords: EML4-ALK fusion gene, overall survival, non-small cell lung cancer, 
anaplastic lymphoma kinase (ALK)
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O-026: RESPONSE TO FIRST-LINE CHEMOTHERAPY IN A NON 
SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH THE 
EML4-ALK FUSION GENE.
Yosuke Morodomi, Ryo Toyozawa, Eiko Inamasu, Miyako Kojo, Gouji Toyokawa, 
Yoshimasa Shiraishi, Tomoyoshi Takenaka, Fumihiko Hirai, Masafumi Yamaguchi, 
Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose  
Department Of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka/JAPAN
Background: Crizotinib, selective inhibitor of EML4-ALK fusion tyrosine kinase, has been 
approved as a subsequent chemotherapeutic agent for treating non small cell lung cancer 
(NSCLC) by the Health, Labour and Welfare Ministry in Japan. This EML4-ALK fusion 
tyrosine kinase inhibitor is expected to become a key of next generation drug. However, 
there is few knowledge about the response rate of fisrt-line chemotherapy in EML4-ALK 
positive NSCLC patients. Methods: Advanced or postoperative recurrent NSCLC patients 
who are diagnosed as positive for the EML4-ALK fusion gene were enrolled in this 
study. The response rate of first-line chemotherapy in those patients was retrospectively 
evaluated. Results: Eighteen patients with the EML4-ALK fusion gene were analyzed 
(5 males, 13 females). The median age was 47 years (range 27-60). The clinical stage of 
advanced NSCLC patients was IIIA in 2, IV in 12 and 4 had postoperative recurrence. 
The first line chemotherapy regimens were as follows: 5 patients were received Cisplatin/
Carboplatin+Gemcitabine, 4 patients received Cisplatin/Carboplatin+Pemetrexed, 2 
patients recieved Cisplatin+S-1+Radiation, 1 patient received Carboplatin+Paclitaxel+Beva
cizumab, 1 patient received Cisplatin+Vinorelbine+Radiation, 1 patient received Gefitinib 
and 1 patient received Pemetrexed. The response rate was 17% (CR:0, PR:3, SD:4, PD:11). 
Conclusion: Further studies are needed in order to clarify these mechanisms, but NSCLC 
patient with the EML4-ALK fusion gene may be resistant to cytotoxic agents.
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O-027: EXPLORATORY SUBGROUP ANALYSIS OF CRIZOTINIB 
EFFICACY AND SAFETY IN ASIAN AND NON-ASIAN PATIENTS 
WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CAN-
CER (NSCLC) ENROLLED IN A GLOBAL PHASE II STUDY 
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Background: Approximately 3–5% of NSCLCs harbor ALK gene rearrangements, with 
no apparent difference in incidence by ethnicity. Crizotinib is a first-in-class, oral, small-
molecule, competitive ALK inhibitor with anti-c-MET and anti-ROS activity. A previous 
report indicated higher crizotinib exposure in Asian versus non-Asian patients (Ou 
APLCC 2010).  Methods: PROFILE 1005 is an ongoing, global, multicenter, open-label, 
single-arm, phase II study evaluating the safety and efficacy of crizotinib (250 mg BID in 
3-week cycles) in patients with ALK-positive advanced NSCLC who progressed after ≥1 
chemotherapy for recurrent/advanced/metastatic disease (including patients with treated 
brain metastases). Central confirmation of ALK-positivity was required for the original 
patient sample (250 patients); subsequent protocol revisions extended the sample size and 
permitted inclusion of patients on a case-by-case basis using local ALK testing. Disease 
response was evaluated using RECIST 1.1 every 6 weeks; safety evaluations were every 
3 weeks. Results: As of January 1, 2012, 901 patients were enrolled and treated (safety 
population, N=901; Asian, n=379; non-Asian, n=522). The mature response-evaluable 
population comprised 259 of the first 261 patients enrolled and treated as of February 
1, 2011; all were centrally confirmed as ALK-positive by FISH (Asian, n=93; non-Asian, 
n=166). Median duration of treatment was 48 weeks (n=259). Objective response rates 
(ORRs) for Asian and non-Asian patients were 70% (95% CI: 60–79) and 54% (95% CI: 
46–62), respectively. In the safety population (N=901), 12% of Asian patients and 18% of 
non-Asian patients discontinued treatment due to AEs. Treatment-related AEs occurring 
in ≥10% of patients are summarized (table). Treatment-related grade 3/4 SAEs occurred in 
2.4% (9/379) and 6.7% (35/522), and grade 5 SAEs in 1.1% (4/379) and 1.3% (7/522) of Asian 
and non-Asian patients, respectively. Treatment-related pneumonitis occurred in 4 Asian 
patients (grade 3, n=1; grade 4, n=3) and 7 non-Asian patients (grade 2, n=3; grade 3, n=2; 
grade 4, n=1; grade 5, n=1). Renal cysts occurred in 7 Asian patients (grade 1, n=5; grade2, 










(%) grade 3/4 (%) 
Vision disorder* 53 0 51 <1 
Constipation 33 0 24 0 
Diarrhea 41 <1 41 2 
Nausea 45 <1 48 1 
Edema* 17 <1 32 <1 
Vomiting 41 1 38 1 
Fatigue* 18 1 28 3 
Dysgeusia 22 0 13 0 
Decreased 
appetite 23 0 15 <1 
Dizziness 15 0 7 0 
Headache 22 0 3 0 
ALT elevation* 18 3 15 5 
AST elevation 12 2 12 2 
Neutropenia* 13 10 10 4 
*AEs that may be 
underestimated 
by use of single 
preferred terms 
are summarized 
by clustered terms 
 
Conclusion: The ORR with crizotinib appears to be higher in Asian than non-Asian 
patients. AE profiles were similar between the two groups, with the exception of slightly 
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increased frequencies of dizziness, headache, constipation, dysgeusia, decreased appetite 
and grade 3/4 neutropenia in Asian patients and edema and fatigue in non-Asian 
patients. The relationship between crizotinib exposure and efficacy warrants further 
investigation.
Keywords: crizotinib, ALK-positive NSCLC, efficacy, safety
APLCC ORAL ABSTRACT SESSION IV - November 27, 2012 15:15-16:15
O-028: CLINICAL ACTIVITY OF CRIZOTINIB IN PATIENTS WITH 
ADVANCED NON-SMALL CELL LUNG CANCER HARBORING THE 
ROS1 GENE REARRANGEMENT
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Background: Chromosomal rearrangements in the receptor tyrosine kinase (RTK) 
gene ROS1 define a new molecular subset of non-small cell lung cancer (NSCLC). 
Crizotinib, a small-molecule inhibitor of ALK and MET, inhibits ROS1 kinase activity 
in cell lines. We examined the efficacy and safety of crizotinib in patients with advanced, 
ROS1-rearranged NSCLC. Methods: Patients with advanced NSCLC harboring ROS1 
rearrangements, as determined using a break-apart FISH assay, were recruited into 
an expansion cohort of an early phase I study of crizotinib. Patients were treated with 
crizotinib at the standard oral dose of 250 mg twice daily. The objective response rate 
(ORR) was determined based on Response Evaluation Criteria in Solid Tumors version 
1.0. The disease control rate (DCR: percent stable disease [SD] + partial response [PR] 
+ complete response [CR]) was evaluated at weeks 8 and 16. Results: Twenty patients 
with ROS1-positive NSCLC have enrolled in the trial to date. At the time of data cut-off 
(April 19, 2012), 15 patients had received crizotinib and 14 were evaluable for response. 
The median age was 54 years (range, 31–72). Fourteen patients were never-smokers. All 
had NSCLC with an adenocarcinoma histology that was confirmed negative for ALK 
rearrangement. The median number of prior treatments was 1 (range, 0–6). The first 
patient with ROS1-positive disease received crizotinib on October 19, 2010. At data 
cut-off, among response-evaluable patients, the ORR was 57% (8/14; 95% CI, 28.9–82.3), 
with 7 PRs and 1 CR. Four patients had SD, one of which was unconfirmed as a PR. The 
DCR at 8 weeks was 79% (11/14). Median duration of treatment was 25.7 weeks (range, 
0.1+ to 65.3+), and 12 of the 15 patients who had received crizotinib at data cut-off 
were continuing on study. The pharmacokinetics, antitumor activity, and safety profile 
of crizotinib in this group of patients were similar to those observed in patients with 
ALK-positive NSCLC. Updated efficacy results will be presented, as enrollment is active 
and ongoing. Conclusion: Crizotinib is associated with clinically significant antitumor 
activity in patients with ROS1-positive NSCLC. Similar to ALK, ROS1 rearrangement 
defines another unique molecular subset of NSCLC for which crizotinib therapy may be 
highly effective. Importantly, this study represents the first clinical investigation of ROS1 
gene rearrangements as a therapeutic target in cancer.
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O-029: PARACRINE RECEPTOR LIGANDS ACTIVATE BYPASS 
TRACTS AND CAUSE ALK INHIBITOR RESISTANCE IN EML4-ALK 
LUNG CANCER CELLS
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Background: Cancer cell microenvironments, including host cells, can critically affect 
cancer cell behaviors, including drug sensitivity. We recently reported that hepatocyte 
growth factor (HGF), the ligand of a tyrosine kinase receptor Met, can be produced not 
only by cancer cells but also host fibroblasts, activates Met and the downstream PI3K/
Akt pathway and triggers resistance to EGFR inhibitors in EGFR mutant lung cancer 
cells. Crizotinib, a dual inhibitor of ALK and Met, shows dramatic effects against EML4-
ALK lung cancer cells, but these cells can acquire resistance by several mechanisms, 
including ALK amplification and gatekeeper mutation. Although selective ALK 
inhibitors can overcome crizotinib resistance due to these mechanisms, these cells may 
become resistant to these inhibitors. Here, we determined whether microenvironmental 
factors trigger ALK inhibitor resistance in EML4-ALK lung cancer cells. Methods: 
We tested the effects of ligands produced by endothelial cells and fibroblasts, and the 
cells themselves, on the susceptibility of EML4-ALK lung cancer cell lines to crizotinib 
and TAE684, a selective ALK inhibitor active against cells with ALK amplification and 
gatekeeper mutations, both in vitro and in vivo. Results: EML4-ALK lung cancer cells 
were highly sensitive to ALK inhibitors. EGF receptor (EGFR) ligands, such as EGF, 
TGF-α, and HB-EGF, activated EGFR and triggered resistance to crizotinib and TAE684 
by transducing bypass survival signaling through Erk1/2 and Akt. Hepatocyte growth 
factor (HGF) activated Met/Gab1 and triggered resistance to TAE684, but not crizotinib, 
which inhibits Met. Endothelial cells and fibroblasts, which produce the EGFR ligands 
and HGF, respectively, decreased the sensitivity of EML4-ALK lung cancer cells to 
crizotinib and TAE684, respectively. EGFR-TKIs resensitized these cells to crizotinib 
and Met-TKI to TAE684 even in the presence of EGFR ligands and HGF, respectively. 
Conclusion: Our findings suggest that paracrine receptor activation by ligands from the 
microenvironment may trigger resistance to ALK inhibitors in EML4-ALK lung cancer 
cells, and provide a rationale for targeting receptor ligands in the microenvironment for 
more successful treatment with ALK inhibitors. These observation further raise clinical 
questions which classes ALK inhibitors are more beneficial for EML4-ALK lung cancer 
patients.
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O-030: EVALUATION OF PTPRF EXPRESSION AS A POTENTIAL 
PROGNOSTIC/PREDICTIVE BIOMARKER FOR ERLOTINIB-
TREATED NON-SMALL CELL LUNG CANCER (NSCLC)
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Background: Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine-kinase 
inhibitor that has demonstrated efficacy in the maintenance and second-/third-line 
treatment of unselected NSCLC patients. Erlotinib has also demonstrated efficacy in the 
first-line treatment of patients with EGFR mutation-positive NSCLC. The establishment of 
predictive biomarkers, particularly for wild-type disease, could potentially help patients, 
physicians and payers optimize erlotinib treatment decisions. PTPRF (protein receptor-
type tyrosine phosphatase F), is involved in EGFR dephosphorylation, and we aimed to 
establish whether it has a role as a predictive/prognostic biomarker for erlotinib treatment 
of NSCLC. Methods: MERIT was a single-arm, phase II clinical trial (1) in which all 
patients had biopsy performed by bronchoscopy before starting erlotinib treatment 
(150mg/day orally). Biopsies were snap frozen, and laser capture microdissection of tumor 
cells was used to isolate and amplify mRNA. Affymetrix HGU-133A microarrays were 
used to analyse gene expression profiles. Exploratory statistical methods identified several 
gene candidates by comparing benefitting and non-benefitting patients. Gene candidates 
were analyzed and confirmed in formalin-fixed paraffin embedded (FFPE) tissue using 
qRT-PCR. To examine the marker of interest (PTPRF) further, FFPE tissue from the 
independent randomized phase III SATURN trial (2) was also analyzed using qRT-PCR 
and assessed for prognostic/predictive markers. High (>median) and low (<median) gene 
expression was assessed for correlations with progression-free survival (PFS) and overall 
survival (OS). Results: PTPRF expression was greater in patients who benefited from 
erlotinib treatment in MERIT, compared with those who did not benefit. SATURN also 
suggested a predictive role for PTPRF; a larger treatment effect was observed in patients 
with high levels of PTPRF (Table). Multivariate analysis of these data will be presented. 
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O-031: FIBROBLAST GROWTH FACTOR RECEPTOR 1 GENE 
AMPLIFICATION IS ASSOCIATED WITH POOR SURVIVAL AND 
CIGARETTE SMOKING DOSAGE IN RESECTED SQUAMOUS CELL 
LUNG CANCER PATIENTS
Byoung Chul Cho  
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Background: Fibroblast growth factor receptor 1 (FGFR1) is one of the most commonly 
amplified genes in human cancer. FGFR1 plays crucial roles in cancer development, 
and are targets for dysregulation by amplification, point mutations, or translocation. 
Amplification or activation of FGFR1 has been reported in oral squamous carcinoma, 
esophageal squamous cell carcinomas, ovarian cancer, bladder cancer, prostate cancer, 
rhabodomyosarcoma, and lung cancer. This study was performed to investigate 
the frequency and the prognostic role of fibroblast growth factor receptor 1 (FGFR1) 
amplification in surgically resected lung squamous cell cancer (SqCC) patients and the 
association between smoking and FGFR1 amplification. Methods: Gene copy number of 
FGFR1 was investigated in microarrayed tumors from 262 SqCC patients with available 
tumor tissue as well as smoking and survival data (median follow-up 54.3 months). Gene 
copy number was evaluated by fluorescent in situ hybridization (FISH), and a FGFR1 
amplified tumor (FGFR1 amp+) was defined as a tumor with nine or more copies of FGFR1 
based on FISH analysis.  Results: Among 262 cases, the frequency of FGFR1 amp+ was 
13.0%. Patients with FGFR1 amp+ had significantly shorter disease-free survival (DFS) 
(26.9 vs. 94.6 months, P < 0.0001) as well as shorter overall survival (OS) (51.2 vs. 115.0 
months, P = 0.002) than those without FGFR1 amp+. Multivariate modeling confirmed 
that patients with FGFR1 amp+ had a significantly greater risk of recurrence and death 
than those without FGFR1 amp+ after adjusting for sex, smoking, pathologic stage, and 
adjuvant chemotherapy (AHR 2.24, 95% CI 1.45 -3.45, P < 0.001, DFS; AHR 1.82, 95% CI 
1.15-2.89, P = 0.01, OS). In FGFR1 amp+ group, the patients treated with adjuvant therapy 
showed the longer DFS and OS than those without adjuvant chemotherapy (12.7 vs. 40.8 
months in adjuvant chemotherapy, P < 0.0001 in DFS; 36.2 vs. 59.4 months in adjuvant 
chemotherapy, P = 0.004 in OS). FGFR1 amp- group patients did not benefit from adjuvant 
chemotherapy. The frequency of FGFR1 amp+ was significantly higher in current smokers 
than former and never smokers (28.9 vs. 2.5 vs. 0%, Ptrend < 0.0001). In terms of smoking 
dosage, the incidences of FGFR1 amp+ were 19.2% (15/78) in patients with 45 packs-years or 
more, 15.7% (14/89) in patients with 30-44 packs-years, 10.2% (4/39) in patients with 20-29 
packs-years, 5.2%(1/19) in patients with 10-19 packs-years, and 0% (0/37) in never smokers. 
As the smoking dosage (packs-years) increased, so did the incidence of FGFR1 amp+ (Ptrend 
= 0.002). Conclusion: FGFR1 amplification is an independent negative prognostic factor 
in surgically resected SqCC and is associated with cigarette smoking in a dose-dependent 
manner. FGFR1 amplification is a relevant therapeutic target in Asian lung SqCC patients.
Keywords: Fibroblast growth factor receptor, Non-small-cell lung cancer, Squamous 
Cell carcinoma, Predictive biomarker
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O-032: EML4-ALK REARRANGEMENT PREDICTED SIMILAR CHE-
MOTHERAPY RESPONSE COMPARED TO EGFR MUTANT, KRAS 
MUTANT AND TRIPLE NEGATIVE PATIENTS WITH ADVANCED 
NON-SMALL-CELL LUNG CANCER
Zhu Zeng1, Xu-chao Zhang2, Fei-yu Niu2, Zhi Xie2, Yi-long Wu2  
1Lung Cancer, Guangdong Lung Cancer Institute, Guangzhou/CHINA, 21. Guangdong 
Lung Cancer Institute, Guangdong General Hospital And Guangdong Academy Of 
Medical Sciences, Guangzhou, Guangzhou/CHINA
